NCT05596526View on ClinicalTrials.gov

Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis Patients

PHASE4RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
ShinglesZoster
Interventions
BIOLOGICAL

recombinant zoster vaccine

Shingrix® vaccine will be administered in two vaccinations on Day0 and Day60

Trial Locations (1)

1205

RECRUITING

University Hospitals of Geneva, Geneva

All Listed Sponsors
lead

Prof Patrice Lalive

OTHER